Workflow
Intraocular lens
icon
Search documents
Ocumetics Engages The Howard Group to Direct Capital Market & Corporate Digital Communications Programs
Thenewswire· 2025-09-12 23:50
Group 1 - Ocumetics Technology Corp. has engaged Howard Group Inc. as its investor relations communications advisor for a six-month period starting September 1, 2025, with a monthly compensation of $10,000 and additional fees as needed [1][2] - The agreement includes granting Howard Group stock options to purchase up to 250,000 common shares for two years at market price, with an additional 250,000 options if the contract is extended [1] - The engagement is subject to the approval of the TSX Venture Exchange, which is currently pending [2] Group 2 - Ocumetics is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [3] - The company is in the preclinical study phase of developing a revolutionary intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses [4] - This intraocular lens is intended to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses [4]
Ocumetics Announces Completion of First Tranche of Unit Private Placement
Thenewswire· 2025-07-17 13:00
Core Viewpoint - Ocumetics Technology Corp. has successfully completed the first tranche of a private placement, raising a total of $1,124,362 through the issuance of 3,212,462 units at a price of $0.35 per unit [1][2]. Group 1: Private Placement Details - The units issued consist of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of an additional common share at an exercise price of $0.50 for 24 months [2]. - The total offering aims to raise up to $2,100,000 by issuing up to 6,000,000 units at the same price, with the remaining tranches to be closed subsequently [5]. - The net proceeds from the offering are intended for ongoing research and development, although actual allocation may vary based on future operations [5]. Group 2: Agent and Related Transactions - Ocumetics paid $68,610 to Numus Capital Corp. for their services as an agent and issued warrants allowing Numus Capital to purchase up to 196,029 common shares at $0.50 per share for 24 months [3]. - The private placement involved a related party transaction, as a director of the Corporation participated, and the transaction was approved unanimously by the board [6]. Group 3: Company Overview - Ocumetics Technology Corp. is focused on developing advanced vision correction solutions, including innovative intraocular lenses aimed at enhancing the quality of life for patients [7][8]. - The company is currently in the preclinical study stage of a technology designed to potentially eliminate the need for corrective lenses by allowing the eye's natural muscle activity to shift focus [9].